Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

Hemophilia B Clinical Trial

Official title:

Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B With Detectable Pretreatment AAV5 Neutralizing Antibodies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06003387
• Other study ID #: CSL222_3005
• Status: Recruiting
• Phase: Phase 3
• Start date: January 30, 2024
• Est. completion date: October 2028

Study information

• Verified date: April 2024
• Source: CSL Behring
• Contact: Trial Registration Coordinator
• Phone: 1-610-878-4000
• Email: clinicaltrials[@]cslbehring.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the risk of bleeding due to failure of expected pharmacological action of CSL222 in adults with severe or moderately severe hemophilia B with detectable pretreatment AAV5 Nabs.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 35
• Est. completion date: October 2028
• Est. primary completion date: October 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Has congenital hemophilia B with known severe or moderately severe FIX deficiency (= 2% of normal circulating FIX) for which the participant is on continuous routine FIX prophylaxis
• Has 2 consecutive detectable AAV5 NAb titer results between Screening and Visit L-Final using a validated AAV5 NAb assay (based on central laboratory results)
• Has > 150 previous exposure days to FIX replacement therapy
• Has been on stable FIX prophylaxis for at least 2 months before Screening
• Has demonstrated capability to independently, accurately, and in a timely manner complete the eDiary during the Lead-in Period, as judged by the investigator
• Acceptance to barrier contraception protection for 1 year starting the day of CSL222 treatment
• Able to provide informed consent after receipt of verbal and written information about the study
• Investigator believes that the participant (or the participant's legally acceptable representative[s]) understands the nature, scope, and possible consequences of the study and is able to adhere to the study procedures.

Exclusion Criteria:

• History of FIX inhibitors or positive FIX inhibitor test at Screening or Visit L (lead-in period)-Final (based on central laboratory results)
• Screening and Visit L-Final laboratory values that meet the definition of Severe Hepatic Impairment per Common Terminology Criteria for Adverse Events (CTCAE) (based on central laboratory results)
• ALT > 2 × the upper limit of normal (ULN) at Screening and Visit L-Final (based on central laboratory results)
• Any condition other than hemophilia B resulting in an increased bleeding tendency
• Any uncontrolled or untreated infection (human immunodeficiency virus [HIV], hepatitis C, etc.) or any other significant concurrent, uncontrolled medical condition evaluated by the investigator to interfere with adherence to the clinical study protocol or with the degree of tolerance to CSL222.
• Thrombocytopenia, defined as a platelet count below 50 × 10^9/L, at Screening and Visit L-Final (based on central laboratory results)
• Known history of allergy to corticosteroids or known medical condition that would require chronic administration of steroids.
• Known uncontrolled allergic conditions or allergy / hypersensitivity to any component of the CSL222 excipients
• Previous gene therapy treatment
• Receipt of an experimental agent or device within 60 days before Screening until the end of the study.
• Note: Other protocol pre-specified exclusion criteria may apply.

Related Conditions & MeSH terms

• Hemophilia A
• Hemophilia B

Intervention

Genetic:
• CSL222 (AAV5-hFIXco-Padua)
Administered as a single IV infusion.

Locations

Country	Name	City	State
Canada	McMaster University - Hamilton - 12400017	Hamilton	Ontario
Israel	Sheba Medical Center - 37600004	Tel Hashomer
United States	University of Michigan - 84000285	Ann Arbor	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
CSL Behring

Countries where clinical trial is conducted

United States,  Canada,  Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Annualized Bleeding Rate (ABR)	The total, spontaneous, joint, and Factor IX (FIX)-treated bleeding episodes will be analyzed. ABR is calculated as the total bleeding episodes divided by the total time at risk.	Post-dose: Months 7 to 18
Secondary	Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs (TESAEs), and TEAEs of Special Interest (TEAESIs)		Post-dose: At Months 6,12, and 18
Secondary	Percentage of Participants With TEAEs, TESAEs, and TEAESIs		Post-dose: At Months 6,12, and 18
Secondary	Number of TEAEs, TESAEs, and TEAESIs		Post-dose: At Months 6,12, and 18
Secondary	Number of Participants with Change From Baseline in Abdominal Ultrasound		Baseline up to 18 months post dose
Secondary	Number of Participants Who Develop Factor IX (FIX) Inhibitors		Up to 18 months post dose
Secondary	Percentage of Participants who Develop FIX Inhibitors		Up to 18 months post dose
Secondary	Number of Participants with Clinically Significant Hematology and Serum Chemistry Parameters		Up to 18 months post dose
Secondary	Percentage of Participants With Clinically Significant Hematology and Serum Chemistry Parameters		Up to 18 months post dose
Secondary	Number of Participants with Clinically Significant Change in Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST)		Up to 18 months post dose
Secondary	Percentage of Participants With Clinically Significant Change in ALT or AST		Up to 18 months post dose
Secondary	Number of Participants Treated With Corticosteroids For Change in ALT or AST		Up to 18 months post dose
Secondary	Percentage of Participants Treated With Corticosteroids For Change in ALT or AST		Up to 18 months post dose
Secondary	Number of Participants With Clinically Significant Alpha-fetoprotein (AFP)		Up to 18 months post dose
Secondary	Percentage of Participants With Clinically Significant AFP		Up to 18 months post dose
Secondary	Number of Participants with Infusion Related Reactions or Hypersensitivity Reactions		Up to 18 months post dose
Secondary	Percentage of Participants With Infusion Related Reactions or Hypersensitivity Reactions		Up to 18 months post dose
Secondary	Number of Participants With the Endogenous FIX Activity		Post-dose: At Months 6, 12, and 18
Secondary	Change From Baseline in the Endogenous FIX Activity		Baseline up to Months 6, 12, and 18 post dose
Secondary	Annualized Consumption of FIX Replacement Therapy		Post-dose: Months 7 to 18
Secondary	Annualized Infusion Rate of FIX Replacement Therapy		Post-dose: Months 7 to 18
Secondary	Percentage of Participants Remaining Free of Previous Continuous Routine FIX Prophylaxis		Post-dose: Months 7 to 18
Secondary	ABR for Spontaneous Bleeding Episodes, Joint Bleeding Episodes, and FIX-treated Bleeding Episodes Separately		Post-dose: Months 7 to 18
Secondary	Correlation Analysis of FIX Activity Levels		Post-dose: Months 6 to 18
Secondary	Number of Participants With New Target Joints and Resolved New or Preexisting Target Joints	Target joint is defined as 3 or more spontaneous bleeding episodes into a single joint.	Post-dose: Months 7 to 18
Secondary	Number of Participants With Zero Bleeds Following Stable FIX Expression		Post-dose: Months 7 to 18
Secondary	Percentage of Participants With Zero Bleeds Following Stable FIX Expression		Post-dose: Months 7 to 18
Secondary	Hemophilia Quality of Life Questionnaire (Hem-A-QoL) Total Score and Treatment Domain Score	The Hem-A-QoL (Hemophilia Quality of Life Questionnaire for Adults) consists of 46 items comprising 10 domains: physical health, feelings, treatment, work and school, dealing with hemophilia, family planning, future, partnerships and sexuality, sports and leisure, and view of yourself for which responses will be recorded from 5 options (never, seldom, sometimes, often, and always; for some items, there is also a "not applicable" option). The Hem-A-QoL Total Score and Treatment Domain Score range from 0 to 100, with lower scores reflecting a better quality of life.	Post-dose: Months 6 to 18
Secondary	Change From Baseline in the Hem-A-QoL Total Score and Treatment Domain Score	The Hem-A-QoL consists of 46 items comprising 10 domains: physical health, feelings, treatment, work and school, dealing with hemophilia, family planning, future, partnerships and sexuality, sports and leisure, and view of yourself for which responses will be recorded from 5 options (never, seldom, sometimes, often, and always; for some items, there is also a "not applicable" option). The Hem-A-QoL Total Score and Treatment Domain Score range from 0 to 100, with lower scores reflecting a better quality of life. The change from baseline in the Hem-A-QoL Total Score and Treatment Domain Score will be determined.	Baseline, Months 6 to 18 post dose
Secondary	EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS) Overall Score	The EQ-5D-5L questionnaire visual analogue scale (VAS) measures overall health status on a vertical VAS ranging from 0 to 100. A higher score indicates better quality of life.	Post-dose: Months 6 to 18
Secondary	EQ-5D-5L Index Scores	The EQ-5D-5L questionnaire descriptive system of health-related quality of life consists of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) for which responses will be recorded on 5 levels of severity (no problems, slight problems, moderate problems, severe problems, and extreme problems). The responses will be converted into a single index utility score (typically between -0.6 and 1). A higher score indicates better quality of life.	Post-dose: Months 6 to 18
Secondary	Change from Baseline in the EQ-5D-5L VAS Score	The EQ-5D-5L questionnaire visual analogue scale (VAS) measures overall health status on a vertical VAS ranging from 0 to 100. A higher score indicates better quality of life. The change from baseline in the EQ-5D-5L VAS score will be determined.	Baseline, Months 6 to 18 post dose
Secondary	Change From Baseline in the EQ-5D-5L Index Scores	The EQ-5D-5L questionnaire descriptive system of health-related quality of life consists of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) for which responses will be recorded on 5 levels of severity (no problems, slight problems, moderate problems, severe problems, and extreme problems). The responses will be converted into a single index utility score (typically between -0.6 and 1). A higher score indicates better quality of life. The change from baseline in the EQ-5D-5L index score will be determined.	Baseline, Months 6 to 18 post dose